MX2012001144A - Compuestos para el tratamiento de inflamacion. - Google Patents

Compuestos para el tratamiento de inflamacion.

Info

Publication number
MX2012001144A
MX2012001144A MX2012001144A MX2012001144A MX2012001144A MX 2012001144 A MX2012001144 A MX 2012001144A MX 2012001144 A MX2012001144 A MX 2012001144A MX 2012001144 A MX2012001144 A MX 2012001144A MX 2012001144 A MX2012001144 A MX 2012001144A
Authority
MX
Mexico
Prior art keywords
treatment
inflammation
compounds
relates
benzylideneaminoguanidines
Prior art date
Application number
MX2012001144A
Other languages
English (en)
Inventor
Arne Boman
Elisabeth Seifert
Per Lek
Niklas Palmqvist
Anders Sjoedin
Christina Wenglen
Christofer Flood
Lennart Lundberg
Original Assignee
Anamar Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0913427A external-priority patent/GB0913427D0/en
Priority claimed from GBGB1005495.5A external-priority patent/GB201005495D0/en
Priority claimed from GBGB1010671.4A external-priority patent/GB201010671D0/en
Application filed by Anamar Ab filed Critical Anamar Ab
Publication of MX2012001144A publication Critical patent/MX2012001144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de bencilidenoaminoguanidi nas para el tratamiento de inflamación y dolor. En una modalidad preferida, la invención se refiere al uso de N-(2-cloro-3,4-dimeto xibencilidenamino)guanidina para el tratamiento de artritis reumatoide.
MX2012001144A 2009-07-31 2010-07-30 Compuestos para el tratamiento de inflamacion. MX2012001144A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0913427A GB0913427D0 (en) 2009-07-31 2009-07-31 Compounds for treatment of imflammation
GBGB1005495.5A GB201005495D0 (en) 2010-03-31 2010-03-31 Compounds for treatment of inflammation
GBGB1010671.4A GB201010671D0 (en) 2010-06-24 2010-06-24 Compounds for treatment of inflammation
PCT/GB2010/001457 WO2011012868A1 (en) 2009-07-31 2010-07-30 Compounds for treatment of inflammation

Publications (1)

Publication Number Publication Date
MX2012001144A true MX2012001144A (es) 2012-05-08

Family

ID=42799430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001144A MX2012001144A (es) 2009-07-31 2010-07-30 Compuestos para el tratamiento de inflamacion.

Country Status (13)

Country Link
US (1) US20120190751A1 (es)
EP (1) EP2470270A1 (es)
JP (1) JP2013500957A (es)
CN (1) CN102573993A (es)
AU (1) AU2010277356A1 (es)
BR (1) BR112012002267A2 (es)
CA (1) CA2769541A1 (es)
GB (1) GB2473095A (es)
IN (1) IN2012DN00928A (es)
MX (1) MX2012001144A (es)
NZ (1) NZ598124A (es)
RU (1) RU2012106467A (es)
WO (1) WO2011012868A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN105561313B (zh) * 2016-01-25 2018-12-25 北京大学 降低5-ht2br含量和抑制其活性的物质在制备治疗和预防动脉粥样硬化产品中的应用
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
US20210177814A1 (en) * 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013622A1 (en) * 1990-03-16 1991-09-19 Beth Israel Hospital Association Use of spiperone as an immunosuppressant and anti-inflammatory agent
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
EP0711553A1 (en) * 1994-08-09 1996-05-15 Mario Cagnoni Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis
AU7802700A (en) * 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US7060711B2 (en) * 2001-10-25 2006-06-13 Biofrontera Bioscience Gmbh Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
BRPI0414622A (pt) * 2003-09-25 2006-11-07 Acadia Pharm Inc métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias
GB0623381D0 (en) * 2006-11-23 2007-01-03 Acure Pharma Ab Use of a compound as VEGF inhibitor
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
GB0715048D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel compounds
EP2411812B1 (en) * 2009-03-24 2013-10-02 AnaMar AB Metabolic profiles

Also Published As

Publication number Publication date
WO2011012868A1 (en) 2011-02-03
GB2473095A (en) 2011-03-02
EP2470270A1 (en) 2012-07-04
CA2769541A1 (en) 2011-02-03
BR112012002267A2 (pt) 2016-11-08
AU2010277356A1 (en) 2012-03-08
GB201012926D0 (en) 2010-09-15
IN2012DN00928A (es) 2015-04-03
US20120190751A1 (en) 2012-07-26
NZ598124A (en) 2014-01-31
CN102573993A (zh) 2012-07-11
RU2012106467A (ru) 2013-09-10
JP2013500957A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2011007930A (es) Conjugados de insulina cristalina.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX2010007490A (es) Preparacion de derivados de sulfamida.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
IN2014CN04014A (es)
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
MY155340A (en) Use of cathepsin c
MX2012001144A (es) Compuestos para el tratamiento de inflamacion.
MY157007A (en) Novel possibility of controlling giardiosis
HK1141436A1 (en) Axomadol for treating pain from arthritis
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
MY179784A (en) Use of cathepsin h
IL223065A (en) Keptapsin protease inhibitors, effective in the treatment of, for example, autoimmune disorders, allergy and chronic pain
LV14346A (lv) 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
WO2011067189A3 (de) Cmet-inhibitoren zur behandlung der endometriose
UA45304U (ru) Способ оценки состояния больного ревматоидным артритом и эффективности его лечения
BR112012025829A2 (pt) ''composição de tratamento, composição líquido e utilização''